Raise by Fusion42
Fusion42 Scout Wire
Capital Reports
Who's InvestingWeekly · Mon 08:00 UTCCapital UnlockedBi-weekly · Wed 08:00 UTC
Benchmarks
Benchmarks HomeFundsRoundsSectors
AI VC IndexCapital FlowAbout

Switch product

Fusion42RaiseScoutWire

Capital Reports

All editionsWho's InvestingWeekly · Mon 08:00 UTCCapital UnlockedBi-weekly · Wed 08:00 UTC

Database & benchmarks

Benchmarks HomeFundsRoundsSectorsStagesAI VC IndexCapital Flow Index

Account

Sign in
← Back

Arch Venture Partners

vc$3BCo-investsLeads rounds

◆ Fund Size

$3B

◆ Check Size

$0.5M→$25.0M

◆ Location

United States

◆ Portfolio

23 companies

◆ Activity

Statusactively investing

◆ Links

Website ↗

◆ Share this fund

ShareXLinkedInEmail

◆ Investment Thesis

Pumping capital into startups and biotech companies, with a recent interest in artificial intelligence and nervous system drug development.

◆ About Arch Venture Partners

ARCH Venture Partners is a leading venture capital firm focused exclusively on early-stage, breakthrough discoveries in life sciences, deep science/physical sciences, and information technology. Their science-first approach involves deep scientific due diligence before company formation, direct co-founding with university researchers and scientists, and long-term commitment with patient capital from concept through growth. They leverage an extended partnership network to build transformative companies.

◆ Sectors

BiotechDrug DiscoveryGenerative AIDigital Health

◆ Stages

seed

◆ Geography Focus

global

◆ Team

NameTitleRoleLinks
Ari Nowacek, M.D, Ph.D.PartnerPartner
Axel Bouchon, Ph.D.Venture PartnerVenture Partner
Brian CuneoSenior PartnerSenior Partner
Carol SuhPartnerPartner
Clinton BybeeCo-founder & Managing Director, EmeritusManaging Director Emeritus
Corey RitterPartnerPartner
David MooreSenior PartnerSenior Partner
George Scangos, Ph.D.Venture PartnerVenture Partner
Inca Coman, Ph.D.Venture PartnerVenture Partner
Jake BauerVenture PartnerVenture Partner
Jason DorenGeneral CounselGeneral Counsel
Jay Parrish, Ph.D.Venture PartnerVenture Partner
John Maraganore, Ph.D.Venture PartnerVenture Partner
Jordan ZwickVenture PartnerVenture Partner
Joseph Jeong, Ph.D.Venture PartnerVenture Partner
Keith CrandellCo-founder & Managing DirectorManaging Director
Kevin HrusovskyVenture PartnerVenture Partner
Kristina BurowManaging DirectorManaging Director
Luciana Borio, M.D.Venture PartnerVenture Partner
Mark McDonnellManaging Director, CFO & CAOManaging Director
Mary Chamberlain-Tharp, Ph.D.Venture PartnerVenture Partner
Mayu Yoshikawa, Ph.D.Venture PartnerVenture Partner
Nilay Thakar, Ph.D.PrincipalPrincipal
Olivia ZetterStrategic Advisor & Venture PartnerStrategic Advisor & Venture Partner
Patrick WeissVenture PartnerVenture Partner
Paul BernsManaging DirectorManaging Director
Peter Mintun, Ph.DAssociateAssociate
Richard Heyman, Ph.D.Venture PartnerVenture Partner
Robert NelsenCo-founder & Managing DirectorManaging Director
Sean KendallPartner (Europe)Partner
Steve Gillis, Ph.D.Managing DirectorManaging Director
Vicki Sato, Ph.D.Venture PartnerVenture Partner

◆ Tracked Investments

◆ Notable Investments

Seaport TherapeuticsDispatch BioBit BioGrailIlluminaDenali TherapeuticsAgios PharmaceuticalsJuno TherapeuticsTwist BioscienceVir BiotechnologyMirador TherapeuticsOratomicTraseOllin BiosciencesPrometheusSonoTheraCountable LabsCREATE MedicinesLightcastSalma Health

◆ Traits

Leads rounds

Co-invests

◆ FAQ

What does Arch invest in?

Arch invests in Biotech, Drug Discovery, Generative AI and Digital Health at the seed stage.

Which geographies does Arch focus on?

Arch focuses on global, and is headquartered in United States.

What is Arch's typical check size?

Arch typically writes checks of $0.5M to $25M.

Which startups has Arch backed?

Arch has 2 tracked investments on Fusion42, including Elle, MD Technologies and Trase.